Xenetic Biosciences, Inc. Announces Directorate Changes
September 30, 2019 at 05:17 pm EDT
Share
On September 25, 2019, Roman Knyazev resigned as a member of the Board of Directors of Xenetic Biosciences, Inc., effective immediately. The resignation did not result from any disagreement with the Company. On September 26, 2019, the Board appointed Grigory G. Borisenko to fill such vacancy to serve as a director of the Company, effective immediately. Mr. Borisenko was not appointed to serve on any committees of the Board upon the commencement of his term as a member of the Board. Grigory G. Borisenko, PhD is the Investment Director of RUSNANO Management Company LLC. Mr. Borisenko has over 20 years of scientific, management and strategic experience in Life science field.
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.